Nurr1 as a Genetic Target for Treating Levodopa-induced Dyskinesias (LIDs) in Parkinson's Disease

 

Executive Summary

 

Patients afflicted with Parkinson’s disease often develop severely debilitating movement disorders as side effects from currently available treatment options. Researchers at MSU propose to use a new gene therapy approach that will both reduce these side effects and prolong the effectiveness of treatment by targeted gene silencing.

 

Description of Technology

 

L-Dopa induced dyskinesia (LID) is a side effect of prolonged chronic use of L-Dopa medication. A hyper-expression of Nurr1 protein in affected brain areas might underlie these side effects. Local injection of vectors encoding target genes in affected striatum can directly prevent the hyper-expression allowing for potentially improved fine-tuned response for motor control.

 

Key Benefits

  • Improved quality of life for Parkinson’s patients
  • Improved and prolonged benefit for movement disorders

 

Applications

  • Treatment of LID in patients with Parkinson’s disease
  • Potentially useful in the treatment of other movement disorders

 

Click Here to View a Poster on this Technology Presented by the Inventors

 

Click Here to View a Second Poster on this Technology Presented by the Inventors

 

Patent Status: 

 

US patent application published, no. 20170198295; foreign patent application published, no. WO2015188077A1

 

Licensing Rights Available

 

Full licensing rights available

 

Inventors: Fredric Manfredsson, Kathy Steece-Collier, Jack Lipton, Timothy Collier, Nicholas Kanaan, Caryl Sortwell

 

Tech ID: TEC2014-0099

 

Alternative contact due to temporary leave:

 

Nina (Isi) Davis, Technology Marketing Manager, email: davisnin@msu.edu, phone (direct): (517)884-1829. 

 

Patent Information:

Category(s):

For Information, Contact:

Randy Ramharack
Technology Manager
Michigan State University
ramharac@msu.edu
Keywords: